December 5, 2023

Summa Therapeutics’ Finesse Injectable PTA Catheter Cleared by FDA

December 5, 2023—Summa Therapeutics recently announced FDA clearance of its Finesse line of injectable angioplasty balloon catheters for percutaneous transluminal angioplasty in the treatment of peripheral artery disease. The Finesse devices are cleared for use in iliac, femoral, popliteal, infrapopliteal, renal arteries, and arteriovenous dialysis access.

Summa plans to launch the product line in the United States in Q4 2023.

According to the company, the Finesse injectable angioplasty balloon catheter provides a port for the injection of radiopaque contrast material or other fluids in addition to performance of balloon angioplasty.

Finesse is designed for complex below-the-knee angioplasty procedures for patients with critical limb-threatening ischemia in the treatment of small arteries in the calf. The combination of a diagnostic catheter and angioplasty balloon catheter in one device is intended to reduce catheter exchanges, lower contrast doses, and shorten procedure times, thereby leading to better patient outcomes and lower costs, stated the company.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

December 5, 2023

Summa Therapeutics’ Finesse Injectable PTA Catheter Cleared by FDA

Current Issue

Keep In Touch